Tegatrabetan(also known as Tegavivint; BC-2059; BC 2059; BC2059) is an orally bioavailable and potent β-catenin inhibitor with potential anticancer activity. BC2059 potently induces apoptosis as a single agent and in combination with bortezomib in multiple myeloma. BC2059 induced apoptosis in 10/10 genetically heterogeneous human myeloma cell lines (HMCL) treated with dosages ranging from 50-500nM.

纯度：≥98%

CAS：1227637-23-1